AEGiS-PRn: The Immune Response Corporation Granted European Notice of Allowance and Russian Patent on HIV Technology

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

The Immune Response Corporation Granted European Notice of Allowance and Russian Patent on HIV Technology

PR Newswire - December 13, 1995

CARLSBAD, Calif., Dec. 13 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received a notice of allowance from the European Patent Office and a patent from the Russian Patent Office regarding its core HIV technology. These patents, issued to inventors Jonas Salk, M.D. and Dennis J. Carlo Ph.D., have been licensed to the company and cover The Immune Response Corporation's lead therapy, a treatment for HIV infection. The company has previously received patents covering this HIV technology from the U.S., Japan and Australia, and has additional international patent applications pending.

These patents on Immune Response's HIV technology complement the company's patents in the autoimmune disease and gene therapy programs. The company's autoimmune disease technology has led to Phase II clinical trials in rheumatoid arthritis and psoriasis. In addition, Immune Response intends to begin Phase I gene therapy trials utilizing the company's patented gene delivery technology by year-end 1996.

The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products in the areas of HIV infection, autoimmune disease and gene therapy.

NOTE: The Immune Response Corporation news releases are available at no charge through PR Newswire's Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference.

NOTE TO EDITORS: Immune Response Corporation press releases are available at no charge through PR Newswire's Company News On-Call fax service and on PR Newswire's Web site. For a menu of Immune Response Corporation press releases or to retrieve a specific release, call 800-758-5804, extension 434675, or http://www.prnewswire.com on the Internet/

CONTACT: Debra L. Altman, investor relations of Immune Response, 619-431-7080/ 08:02 EST

Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951213
PR951224

Copyright © 1995 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .